Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Venglustat malate by Sanofi for Gaucher Disease Type III: Likelihood of Approval
Venglustat malate is under clinical development by Sanofi and currently in Phase III for Gaucher Disease Type III. According to...
Data Insights
Risk adjusted net present value: What is the current valuation of Sanofi's Venglustat malate?
Venglustat malate is a small molecule commercialized by Sanofi, with a leading Phase III program in Fabry Disease. According to...